The semaglutide cohort ( n = 668) compared with the non-GLP-1RA anti-obesity medications cohort ( n = 21,445) had a higher prevalence of adverse socioeconomic determinants of health, problems related to lifestyle, severe obesity, obesity-associated comorbidities and mental disorders
Novo Nordisk denied the allegations
According to the company's website and safety disclosures, you may qualify if: Your Body Mass Index (BMI) is 30 or higher (classified as obese), OR Your BMI is 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, obstructive sleep apnea, or cardiovascular disease, OR Your BMI is above 25 and you may still qualify depending on your overall medical history, as determined by the licensed provider The evaluating clinician reviews your full medical history during intake and makes the final determination about whether treatment is appropriate and safe for your specific situation
Firms & Smooths: Enhances skin texture and elasticity for a visibly firmer, more refined complexion
